Diagens Biotechnology Pursues Hong Kong IPO Listing
Diagens Biotechnology passed a Hong Kong Stock Exchange listing hearing and posted its prospectus on March 15, with Huatai International as sole sponsor. The Hangzhou firm says its iMedImage foundation model powers AI Autovision, a chromosome karyotyping diagnostic system that achieved 100% sensitivity and specificity for numerical abnormalities in a 1,518-sample trial and gained innovative Class 3 designation for accelerated review. Diagens reported RMB112 million revenue in the first three quarters of 2025.
Scoring Rationale
Official prospectus and robust trial claims increase impact, but reliance on company-reported, not independently verified, results limits certainty.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problems
